1-3 of 3
Andrew Christopher William Zannettino, BSc, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

OCT-1 Activity in CML CD34+ Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity.

Jane R Engler, Amity Frede, Verity A Saunders, Andrew Christopher William Zannettino, BSc, PhD, Deborah L White, Timothy P. Hughes, MD
Journal: Blood
Blood (2009) 114 (22): 2189.
https://doi.org/10.1182/blood.V114.22.2189.2189
Published: 2009
Journal Articles

Depletion of Host CD122 + Cells Facilitates Widespread Skeletal Multiple Myeloma Engraftment in NOD/SCID Recipients

Lisa M Freeman, Eugene Petcu, Robert Smith, Ali Salajegheh, Peter Diamond, Andrew Christopher William Zannettino, BSc, PhD, Andreas Evdokiou, John Luff, Dalia Khalil, Frank Vari, Lawrence Catley, MD, Derek Hart, PhD, Slavica Vuckovic
Journal: Blood
Blood (2008) 112 (11): 2734.
https://doi.org/10.1182/blood.V112.11.2734.2734
Published: 2008
Journal Articles

Dasatinib (Sprycel TM ) Inhibits Osteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism

Kate Vandyke, BSc Honours, Andrea Dewar, BSc, PhD, Peter Diamond, BSc, PhD, Stephen Fitter, BSc, PhD, Amanda N Farrugia, BSc Honours, Luen Bik To, MD, Timothy P. Hughes, MD, Andrew Christopher William Zannettino, BSc, PhD
Journal: Blood
Blood (2008) 112 (11): 3214.
https://doi.org/10.1182/blood.V112.11.3214.3214
Published: 2008